Eiger Mountains
Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of rare diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development a... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$11.60
Change (%)0.00 (0.00%)
Volume0
Data as of 09/21/18 4:00 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle
09/04/18Eiger Announces Positive Meeting with FDA on Progeria Program
08/27/18Eiger BioPharmaceuticals to Participate in Investor Conferences
08/13/18Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia
08/10/18Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results
Upcoming EventsMore >>
DateTitle
10/01/18
through
10/03/18
Eiger BioPharmaceuticals at 2018 Cantor Global Healthcare Conference
LocationNYC
10/02/18
Eiger BioPharmaceuticals at the Ladenburg Thalmann 2018 Healthcare Conference
LocationNew York City, NY
10/03/18
through
10/06/18
Eiger BioPharmaceuticals at International HBV Meeting
LocationTaorima, Itlay
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.